Category: Include on Menu
-
Oil Prices Slip as U.S.–Iran Talks Continue; Markets Monitor Rising Venezuelan Supply
Oil prices declined during Asian trading on Friday after the United States and Iran agreed to continue negotiations over Tehran’s nuclear program, while traders also assessed the potential impact of increasing Venezuelan crude exports on global supply balances. Brent crude futures for April delivery fell 0.4% to $70.48 per barrel, while U.S. West Texas Intermediate…
-
Gold Holds Near $5,200/oz as Safe-Haven Demand Drives Strong February Performance
Gold prices were little changed during Asian trading hours on Friday and remained on track for solid monthly gains, supported by persistent safe-haven demand amid heightened geopolitical risks and ongoing economic uncertainty. Concerns surrounding U.S. trade policy shifts, alongside worries about slowing growth across major global economies, encouraged investors to favor defensive assets, allowing bullion…
-
Bitcoin Slips Below $68K as Recovery Fades, On Track for Fifth Monthly Decline
Bitcoin (COIN:BTCUSD) moved lower on Friday, reversing part of its recent rebound from weekly lows as investor risk appetite remained subdued. The world’s largest cryptocurrency is now heading toward a fifth consecutive month of significant losses. The broader cryptocurrency market largely followed Bitcoin’s direction, with digital assets also poised for notable declines in February as…
-
Paramount Poised to Win Warner Deal as Block Jumps — Key Market Movers: Dow Jones, S&P, Nasdaq, Wall Street Futures
U.S. stock index futures moved slightly lower on Friday as investors weighed fresh earnings from major technology companies and reassessed sentiment around artificial intelligence-driven trades. Paramount Skydance (NASDAQ:PSKY) appears set to prevail in the takeover contest for Warner Bros. Discovery (NASDAQ:WBD) after Netflix (NASDAQ:NFLX) withdrew its competing offer, while AI firm Anthropic entered a dispute…
-
Nasdaq Pulls Back Sharply As Nvidia Slumps But Dow Inches Higher
After moving sharply higher over the two previous sessions, stocks gave back some ground during trading on Thursday. The tech-heavy Nasdaq showed a significant move to the downside, although the Dow managed to end the day slightly higher. The Nasdaq climbed well off its early lows but still slumped 273.69 points or 1.2 percent to…
-
Akebia Therapeutics posts mixed Q4 results as revenue beats expectations despite EPS miss
Akebia Therapeutics (NASDAQ:AKBA) reported mixed fourth-quarter 2025 results, with revenue surpassing analyst forecasts while earnings per share fell short of expectations, as investors focused on improving commercial momentum and a stronger balance sheet. Shares of the kidney-disease drug developer rose sharply in premarket trading following the release, reflecting optimism around revenue growth and cash position…
-
Eos Energy reports surging revenue growth, sets ambitious 2026 outlook amid operational turnaround
Eos Energy Enterprises (NASDAQ:EOSE) reported fourth-quarter and full-year 2025 results marked by rapid revenue expansion, improving operational efficiency and a strengthened balance sheet, as the U.S.-based long-duration energy storage developer targets a transition toward scalable, profitable growth. The company, which manufactures zinc-based battery storage systems domestically, delivered record quarterly revenue and introduced initial guidance for…
-
Rackspace Technology narrows losses as cloud shift and AI strategy shape 2026 outlook
Rackspace Technology (NASDAQ:RXT) reported fourth-quarter and full-year 2025 results highlighting improving profitability and a strategic pivot toward enterprise cloud and artificial intelligence services, as the hybrid cloud provider positions itself for renewed growth in 2026. Chief Executive Officer Gajen Kandiah said the latest quarter marked a turning point for the company’s transformation efforts. “Q4 capped…
-
Akebia tops Q4 revenue expectations as Vafseo momentum strengthens outlook
Akebia Therapeutics (NASDAQ:AKBA) reported fourth-quarter revenue that exceeded market expectations and highlighted encouraging early-year commercial performance for its anemia treatment Vafseo, signaling growing momentum following the drug’s initial launch phase. The biopharmaceutical company posted Q4 revenue of $57.62 million, comfortably ahead of the consensus estimate of $46.09 million. Management pointed to improving adoption trends for…
-
Arhaus announces special dividend following record 2025 performance
Arhaus (NASDAQ:ARHS) delivered record financial results for 2025 and announced a special cash dividend, underscoring strong operating performance and a solid balance sheet as the premium home furnishings retailer continues expanding its showroom network. For the full year, net revenue rose 8.5% year over year to $1.379 billion, while gross margin increased to $536 million.…